These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 18525001)
1. Ferumoxytol for treating iron deficiency anemia in CKD. Spinowitz BS; Kausz AT; Baptista J; Noble SD; Sothinathan R; Bernardo MV; Brenner L; Pereira BJ J Am Soc Nephrol; 2008 Aug; 19(8):1599-605. PubMed ID: 18525001 [TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078 [TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796 [TBL] [Abstract][Full Text] [Related]
4. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Schwenk MH Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475 [TBL] [Abstract][Full Text] [Related]
5. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial . Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204 [TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Coyne DW Expert Opin Pharmacother; 2009 Oct; 10(15):2563-8. PubMed ID: 19708851 [TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Schiller B; Bhat P; Sharma A Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802 [TBL] [Abstract][Full Text] [Related]
8. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Lu M; Cohen MH; Rieves D; Pazdur R Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089 [TBL] [Abstract][Full Text] [Related]
9. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549 [TBL] [Abstract][Full Text] [Related]
10. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Hetzel D; Strauss W; Bernard K; Li Z; Urboniene A; Allen LF Am J Hematol; 2014 Jun; 89(6):646-50. PubMed ID: 24639149 [TBL] [Abstract][Full Text] [Related]
11. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Fishbane S; Bolton WK; Winkelmayer WC; Strauss W; Li Z; Pereira BJ Clin Nephrol; 2012 Sep; 78(3):181-8. PubMed ID: 22874106 [TBL] [Abstract][Full Text] [Related]
12. Safety of ferumoxytol in patients with anemia and CKD. Singh A; Patel T; Hertel J; Bernardo M; Kausz A; Brenner L Am J Kidney Dis; 2008 Nov; 52(5):907-15. PubMed ID: 18824288 [TBL] [Abstract][Full Text] [Related]
13. Ferumoxytol: in iron deficiency anaemia in adults with chronic kidney disease. McCormack PL Drugs; 2012 Oct; 72(15):2013-22. PubMed ID: 22994536 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Vadhan-Raj S; Strauss W; Ford D; Bernard K; Boccia R; Li J; Allen LF Am J Hematol; 2014 Jan; 89(1):7-12. PubMed ID: 23983177 [TBL] [Abstract][Full Text] [Related]
15. Intravenous infusions of ferumoxytol compared to oral ferrous sulfate for the treatment of anemia in pregnancy: a randomized controlled trial. Awomolo AM; McWhirter A; Sadler LC; Coppola LM; Hill MG Am J Obstet Gynecol MFM; 2023 Sep; 5(9):101064. PubMed ID: 37348816 [TBL] [Abstract][Full Text] [Related]
16. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Adkinson NF; Strauss WE; Macdougall IC; Bernard KE; Auerbach M; Kaper RF; Chertow GM; Krop JS Am J Hematol; 2018 May; 93(5):683-690. PubMed ID: 29417614 [TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol: an emerging therapeutic for iron deficiency anemia. Sakashita M; Nangaku M Expert Opin Pharmacother; 2023 Feb; 24(2):171-175. PubMed ID: 36471920 [TBL] [Abstract][Full Text] [Related]
18. Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study. Wetmore JB; Weinhandl ED; Zhou J; Gilbertson DT PLoS One; 2017; 12(1):e0171098. PubMed ID: 28135334 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Auerbach M; Strauss W; Auerbach S; Rineer S; Bahrain H Am J Hematol; 2013 Nov; 88(11):944-7. PubMed ID: 23828252 [TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Spinowitz BS; Schwenk MH; Jacobs PM; Bolton WK; Kaplan MR; Charytan C; Galler M Kidney Int; 2005 Oct; 68(4):1801-7. PubMed ID: 16164657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]